Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
 Back to Profile

Saketh Guntupalli

Concepts (293)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Endometrial Neoplasms
21
2025
199
4.880
 Why?
Ovarian Neoplasms
16
2024
562
3.100
 Why?
Genital Neoplasms, Female
7
2024
89
2.880
 Why?
Gynecology
8
2021
168
2.510
 Why?
Enoxaparin
4
2024
63
2.280
 Why?
Carcinoma, Endometrioid
11
2023
50
2.160
 Why?
Pyridones
4
2024
168
2.120
 Why?
Hysterectomy
11
2020
128
2.000
 Why?
Pyrazoles
4
2024
423
1.860
 Why?
Fellowships and Scholarships
5
2018
303
1.740
 Why?
Uterine Cervical Neoplasms
8
2021
254
1.730
 Why?
Obstetrics
4
2020
162
1.660
 Why?
Internship and Residency
6
2020
1132
1.420
 Why?
Poly(ADP-ribose) Polymerase Inhibitors
5
2025
115
1.410
 Why?
Venous Thromboembolism
4
2024
313
1.390
 Why?
Postoperative Complications
8
2024
2639
1.280
 Why?
Neoplasm Recurrence, Local
9
2025
1058
1.260
 Why?
Anticoagulants
4
2024
663
1.250
 Why?
Sexual Dysfunction, Physiological
2
2020
64
1.150
 Why?
Lymph Nodes
3
2017
489
1.100
 Why?
Clinical Competence
5
2020
1094
1.070
 Why?
Neoplasm Staging
18
2024
1371
0.850
 Why?
Uterine Neoplasms
3
2021
109
0.810
 Why?
Indoles
1
2025
410
0.750
 Why?
Middle Aged
44
2025
33228
0.750
 Why?
Female
64
2025
72787
0.750
 Why?
Antineoplastic Combined Chemotherapy Protocols
7
2024
1682
0.740
 Why?
Treatment Adherence and Compliance
1
2021
26
0.720
 Why?
Education, Medical, Graduate
2
2016
481
0.700
 Why?
Pulmonary Embolism
1
2023
225
0.690
 Why?
Aged
34
2025
23794
0.680
 Why?
Carcinosarcoma
3
2017
21
0.670
 Why?
Robotic Surgical Procedures
3
2016
129
0.630
 Why?
Intrauterine Devices
1
2019
31
0.630
 Why?
Ovariectomy
4
2015
152
0.580
 Why?
Laparotomy
2
2015
109
0.580
 Why?
Aged, 80 and over
15
2025
7585
0.580
 Why?
Venous Thrombosis
1
2020
190
0.570
 Why?
Oncologists
1
2018
38
0.570
 Why?
Humans
67
2025
136764
0.570
 Why?
Healthcare Disparities
3
2021
649
0.560
 Why?
Neoplasms
6
2024
2644
0.540
 Why?
Quality of Health Care
2
2021
634
0.540
 Why?
Neoplasm Invasiveness
6
2021
507
0.530
 Why?
Retrospective Studies
17
2024
15504
0.520
 Why?
Sexual Dysfunctions, Psychological
1
2017
34
0.520
 Why?
Medication Adherence
1
2020
466
0.510
 Why?
Attitude
1
2018
259
0.510
 Why?
Minority Groups
1
2018
266
0.500
 Why?
Prognosis
11
2024
4013
0.500
 Why?
Gynecologic Surgical Procedures
3
2024
63
0.490
 Why?
Endometrium
2
2019
58
0.460
 Why?
Radiography, Thoracic
1
2016
167
0.460
 Why?
Hemostasis, Surgical
1
2014
22
0.450
 Why?
Abdominal Abscess
1
2014
27
0.450
 Why?
Gelatin
1
2014
51
0.440
 Why?
Surgeons
1
2018
296
0.430
 Why?
Interpersonal Relations
1
2017
396
0.420
 Why?
Thrombin
1
2014
152
0.420
 Why?
Adult
28
2025
37630
0.410
 Why?
WT1 Proteins
1
2013
15
0.400
 Why?
Robotics
1
2014
94
0.400
 Why?
Estrogen Receptor beta
1
2013
40
0.400
 Why?
Histone-Lysine N-Methyltransferase
2
2024
135
0.390
 Why?
Follow-Up Studies
9
2024
5106
0.380
 Why?
Adenocarcinoma
3
2021
938
0.370
 Why?
Lymphatic Vessels
1
2011
64
0.350
 Why?
Adenocarcinoma, Clear Cell
2
2023
14
0.340
 Why?
Disease-Free Survival
6
2019
685
0.330
 Why?
Preoperative Care
3
2017
356
0.320
 Why?
Smooth Muscle Tumor
1
2009
6
0.310
 Why?
Lymph Node Excision
3
2017
170
0.310
 Why?
Leiomyosarcoma
1
2009
28
0.310
 Why?
Sarcoma, Alveolar Soft Part
1
2008
6
0.290
 Why?
United States
14
2024
14691
0.290
 Why?
Survival Rate
6
2021
1962
0.280
 Why?
Neoplasm Grading
7
2019
305
0.270
 Why?
Radiotherapy, Adjuvant
3
2018
219
0.270
 Why?
Neoplasms, Second Primary
2
2019
116
0.270
 Why?
Combined Modality Therapy
3
2020
1231
0.260
 Why?
Chemotherapy, Adjuvant
3
2018
387
0.260
 Why?
Insurance, Health
3
2018
280
0.250
 Why?
Pregnancy Complications
2
2014
524
0.250
 Why?
Cross-Sectional Studies
5
2017
5423
0.240
 Why?
Risk Factors
7
2024
10326
0.240
 Why?
Maintenance Chemotherapy
1
2025
35
0.240
 Why?
Cohort Studies
5
2021
5701
0.240
 Why?
Insurance Coverage
2
2018
229
0.240
 Why?
Young Adult
7
2021
13129
0.230
 Why?
Paclitaxel
6
2024
227
0.230
 Why?
Lymphatic Metastasis
2
2019
351
0.220
 Why?
Databases, Factual
3
2021
1351
0.220
 Why?
Doxorubicin
2
2024
362
0.220
 Why?
Biomarkers, Tumor
4
2023
1272
0.210
 Why?
Self Report
2
2018
822
0.210
 Why?
Nomograms
2
2021
54
0.210
 Why?
Chemoradiotherapy
1
2024
225
0.200
 Why?
Immunoglobulin M
1
2024
289
0.200
 Why?
Factor Xa Inhibitors
1
2024
172
0.200
 Why?
Lung Neoplasms
1
2016
2489
0.200
 Why?
Tertiary Care Centers
1
2023
159
0.200
 Why?
Liver Diseases
1
2005
311
0.190
 Why?
Program Evaluation
2
2018
889
0.190
 Why?
Drug Resistance, Neoplasm
2
2024
800
0.190
 Why?
Organ Sparing Treatments
2
2019
34
0.190
 Why?
Platinum
1
2022
49
0.190
 Why?
Adolescent
6
2021
21382
0.190
 Why?
Quality of Life
4
2024
2878
0.190
 Why?
Enzyme-Linked Immunosorbent Assay
1
2024
851
0.180
 Why?
Length of Stay
3
2015
1205
0.180
 Why?
Immunohistochemistry
2
2023
1733
0.180
 Why?
beta Catenin
2
2023
253
0.180
 Why?
BRCA2 Protein
1
2021
63
0.170
 Why?
BRCA1 Protein
1
2021
76
0.170
 Why?
Double-Blind Method
1
2025
1981
0.170
 Why?
Ovary
2
2019
221
0.170
 Why?
Risk Assessment
4
2024
3432
0.170
 Why?
Treatment Outcome
5
2020
10744
0.160
 Why?
Fallopian Tube Neoplasms
1
2019
17
0.160
 Why?
High-Throughput Nucleotide Sequencing
1
2023
535
0.160
 Why?
Immunoglobulin G
1
2024
887
0.160
 Why?
Cytoreduction Surgical Procedures
1
2020
63
0.160
 Why?
Postoperative Hemorrhage
1
2020
86
0.160
 Why?
Withholding Treatment
1
2020
76
0.160
 Why?
NM23 Nucleoside Diphosphate Kinases
1
2019
2
0.160
 Why?
Age Factors
4
2016
3284
0.150
 Why?
Peritoneal Neoplasms
1
2019
93
0.150
 Why?
Polyethylene Glycols
1
2024
640
0.150
 Why?
Incidence
3
2024
2792
0.150
 Why?
Cisplatin
4
2024
320
0.150
 Why?
Pregnancy
4
2020
6728
0.150
 Why?
CD8-Positive T-Lymphocytes
1
2024
895
0.150
 Why?
Cancer Survivors
1
2023
280
0.140
 Why?
Fibrinolytic Agents
1
2020
270
0.140
 Why?
Randomized Controlled Trials as Topic
2
2021
1462
0.140
 Why?
Stathmin
1
2017
2
0.140
 Why?
Carboplatin
3
2024
142
0.140
 Why?
Carcinoma, Adenosquamous
1
2017
10
0.140
 Why?
Neoadjuvant Therapy
1
2020
403
0.140
 Why?
Blood Loss, Surgical
2
2015
100
0.130
 Why?
Neoplasms, Cystic, Mucinous, and Serous
1
2017
27
0.130
 Why?
Guideline Adherence
1
2021
546
0.130
 Why?
Carcinoma
1
2019
238
0.130
 Why?
Societies, Medical
1
2021
816
0.130
 Why?
Socioeconomic Factors
1
2021
1282
0.130
 Why?
National Cancer Institute (U.S.)
1
2016
47
0.130
 Why?
Case-Control Studies
4
2019
3540
0.130
 Why?
Health Status Disparities
2
2017
283
0.130
 Why?
Benzamides
1
2017
216
0.130
 Why?
Uterus
2
2023
215
0.130
 Why?
Neonatology
1
2016
29
0.130
 Why?
Perioperative Care
1
2018
178
0.130
 Why?
Surgical Oncology
1
2016
27
0.120
 Why?
Carcinoma, Squamous Cell
2
2021
683
0.120
 Why?
Marriage
1
2017
120
0.120
 Why?
Reimbursement Mechanisms
1
2016
84
0.120
 Why?
Bevacizumab
3
2021
135
0.120
 Why?
Piperidines
1
2017
206
0.120
 Why?
Drug Costs
1
2016
106
0.120
 Why?
Anti-N-Methyl-D-Aspartate Receptor Encephalitis
1
2015
17
0.120
 Why?
Pneumonia, Viral
1
2020
368
0.120
 Why?
Coronavirus Infections
1
2020
358
0.120
 Why?
Pregnancy Complications, Neoplastic
1
2015
51
0.110
 Why?
Female Urogenital Diseases
1
2014
7
0.110
 Why?
Mutation
2
2023
3946
0.110
 Why?
Morbidity
1
2015
323
0.110
 Why?
Peritoneal Cavity
1
2014
31
0.110
 Why?
Intraoperative Complications
1
2015
138
0.110
 Why?
Surgical Wound Dehiscence
1
2014
22
0.110
 Why?
Blood Volume
1
2014
61
0.110
 Why?
Hemostatics
1
2014
52
0.110
 Why?
Maternal-Fetal Exchange
1
2015
165
0.110
 Why?
Anti-Inflammatory Agents, Non-Steroidal
1
2017
350
0.110
 Why?
Drainage
1
2014
171
0.100
 Why?
Colposcopy
1
2013
18
0.100
 Why?
Needs Assessment
1
2015
372
0.100
 Why?
Antibodies
1
2015
410
0.100
 Why?
Health Policy
1
2016
385
0.100
 Why?
Patient Readmission
1
2018
694
0.100
 Why?
Referral and Consultation
1
2018
780
0.100
 Why?
Prospective Studies
6
2023
7572
0.090
 Why?
DNA Polymerase II
2
2023
37
0.090
 Why?
Poly-ADP-Ribose Binding Proteins
2
2023
35
0.090
 Why?
Early Detection of Cancer
1
2016
417
0.090
 Why?
Pandemics
1
2020
1613
0.090
 Why?
Clinical Trials as Topic
1
2016
1044
0.090
 Why?
Proportional Hazards Models
3
2021
1261
0.090
 Why?
Surgical Wound Infection
1
2014
305
0.090
 Why?
Kaplan-Meier Estimate
1
2013
888
0.080
 Why?
Fetus
1
2015
806
0.080
 Why?
Benzimidazoles
2
2021
170
0.080
 Why?
Multivariate Analysis
1
2013
1507
0.080
 Why?
Multicenter Studies as Topic
2
2021
308
0.070
 Why?
Metrorrhagia
1
2008
4
0.070
 Why?
Dilatation and Curettage
1
2008
11
0.070
 Why?
Pediatrics
1
2016
1096
0.070
 Why?
Surveys and Questionnaires
2
2018
5742
0.070
 Why?
Male
7
2024
67309
0.070
 Why?
Tumor Suppressor Protein p53
2
2023
528
0.070
 Why?
Quality Improvement
1
2015
1163
0.070
 Why?
SEER Program
2
2018
218
0.070
 Why?
Cell Line, Tumor
2
2024
3405
0.060
 Why?
Models, Biological
1
2014
1773
0.060
 Why?
Rupture, Spontaneous
1
2005
17
0.060
 Why?
Budd-Chiari Syndrome
1
2005
5
0.060
 Why?
Hepatolenticular Degeneration
1
2005
15
0.060
 Why?
HELLP Syndrome
1
2005
6
0.060
 Why?
Hematoma
1
2005
53
0.060
 Why?
Hepatitis B
1
2005
70
0.060
 Why?
Obesity
2
2016
2982
0.060
 Why?
Cost-Benefit Analysis
2
2020
587
0.060
 Why?
Colorado
1
2014
4518
0.050
 Why?
Tomography, X-Ray Computed
1
2014
2667
0.050
 Why?
Histocompatibility Antigens
1
2024
105
0.050
 Why?
Anti-Bacterial Agents
1
2014
1798
0.050
 Why?
DNA Mismatch Repair
1
2023
49
0.050
 Why?
Pre-Eclampsia
1
2005
189
0.050
 Why?
Decision Support Techniques
2
2020
418
0.050
 Why?
Fatty Liver
1
2005
243
0.050
 Why?
Cholestasis
1
2005
232
0.050
 Why?
Acute Disease
1
2005
1004
0.050
 Why?
Hepatitis C
1
2005
267
0.050
 Why?
X-ray Repair Cross Complementing Protein 1
1
2022
13
0.050
 Why?
Medical Futility
1
2022
23
0.050
 Why?
Liposomes
1
2024
220
0.050
 Why?
Claudin-4
1
2022
15
0.050
 Why?
Genes, BRCA2
1
2021
29
0.040
 Why?
Xenograft Model Antitumor Assays
1
2024
868
0.040
 Why?
Genes, BRCA1
1
2021
38
0.040
 Why?
Clinical Trials, Phase I as Topic
1
2021
50
0.040
 Why?
Hematologic Diseases
1
2021
62
0.040
 Why?
Critical Care
1
2005
583
0.040
 Why?
Organoplatinum Compounds
1
2020
45
0.040
 Why?
Topotecan
1
2020
13
0.040
 Why?
Quality-Adjusted Life Years
1
2020
113
0.040
 Why?
Life Style
1
2023
487
0.040
 Why?
DNA Repair
1
2022
231
0.040
 Why?
Injections, Intraperitoneal
1
2019
114
0.040
 Why?
Japan
1
2019
115
0.040
 Why?
Injections, Intravenous
1
2019
206
0.040
 Why?
DNA Damage
1
2022
420
0.040
 Why?
Platinum Compounds
1
2019
10
0.040
 Why?
Infusions, Intravenous
1
2020
412
0.040
 Why?
Microsatellite Instability
1
2019
42
0.040
 Why?
Class I Phosphatidylinositol 3-Kinases
1
2019
95
0.040
 Why?
Angiogenesis Inhibitors
1
2020
226
0.040
 Why?
Gene Expression Regulation, Neoplastic
1
2024
1396
0.040
 Why?
PTEN Phosphohydrolase
1
2019
162
0.030
 Why?
Administration, Oral
1
2020
813
0.030
 Why?
Antineoplastic Agents, Phytogenic
1
2019
190
0.030
 Why?
Survival Analysis
1
2021
1321
0.030
 Why?
Betacoronavirus
1
2020
266
0.030
 Why?
Mice
2
2024
17733
0.030
 Why?
Hospitals, Private
1
2016
12
0.030
 Why?
Health Facility Size
1
2016
11
0.030
 Why?
Cell Proliferation
1
2024
2472
0.030
 Why?
Time Factors
2
2017
6806
0.030
 Why?
Patient Reported Outcome Measures
1
2020
402
0.030
 Why?
Hospitals, Teaching
1
2016
117
0.030
 Why?
Odds Ratio
1
2018
1065
0.030
 Why?
ErbB Receptors
1
2019
613
0.030
 Why?
Social Class
1
2017
281
0.030
 Why?
Medically Uninsured
1
2016
130
0.030
 Why?
Ileus
1
2015
12
0.030
 Why?
Salpingectomy
1
2015
13
0.030
 Why?
Dose-Response Relationship, Drug
1
2019
2052
0.030
 Why?
Urinary Retention
1
2015
21
0.030
 Why?
Income
1
2016
202
0.030
 Why?
Diet
1
2023
1274
0.030
 Why?
Elective Surgical Procedures
1
2016
180
0.030
 Why?
Advisory Committees
1
2016
219
0.030
 Why?
Pelvis
1
2015
102
0.030
 Why?
Disease Models, Animal
1
2024
4281
0.030
 Why?
Critical Pathways
1
2014
88
0.030
 Why?
Papanicolaou Test
1
2013
43
0.030
 Why?
Vaginal Smears
1
2013
57
0.030
 Why?
Urban Population
1
2016
476
0.030
 Why?
Clinical Protocols
1
2014
267
0.020
 Why?
Pregnancy Outcome
1
2015
412
0.020
 Why?
Membrane Proteins
1
2019
1163
0.020
 Why?
Animals
2
2024
36823
0.020
 Why?
Rural Population
1
2016
560
0.020
 Why?
Disease Progression
1
2019
2750
0.020
 Why?
Polymorphism, Single Nucleotide
1
2019
2184
0.020
 Why?
Comorbidity
1
2016
1614
0.020
 Why?
Exercise
1
2023
2043
0.020
 Why?
Biomedical Research
1
2016
688
0.020
 Why?
Curriculum
1
2016
976
0.020
 Why?
Prostatic Neoplasms
1
2016
1034
0.020
 Why?
Colorectal Neoplasms
1
2016
791
0.020
 Why?
Patient Discharge
1
2015
894
0.020
 Why?
Breast Neoplasms
1
2016
2234
0.010
 Why?
Infant, Newborn
1
2015
6033
0.010
 Why?
Guntupalli's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (293) concept(s)
_
Co-Authors Expand Description
See all (35) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)